Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme (Q46689887)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme |
scientific article |
Statements
1 reference
Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme (English)
1 reference
Chris J Tyrrell
1 reference
Heather Payne
1 reference
William A See
1 reference
David G McLeod
1 reference
Manfred P Wirth
1 reference
Peter Iversen
1 reference
Jon Armstrong
1 reference
Clive Morris
1 reference
'Casodex' Early Prostate Cancer Trialists Group
1 reference
1 July 2005
1 reference
76
1 reference
1
1 reference
4-10
1 reference